Ash Stevens Inc. CEO to Chair Session On Cancer Drug Development at American Association for Cancer Research Annual Meeting
Ash Stevens Inc.™ (ASI) President and CEO Dr. Stephen Munk will chair an educational session for the Chemistry in Cancer Research Working Group (CICR) at the American Association for Cancer Research (AACR) annual meeting on Saturday, April 12 at the San Diego Convention Center. Dr. Munk's session will highlight the unique developmental challenges of safely manufacturing highly potent active pharmaceutical ingredients (APIs) used in cancer drugs.
Detroit, MI (PRWEB) April 12, 2008
Detroit-April 12, 2008-Ash Stevens Inc.™ (ASI) President and CEO Dr. Stephen Munk will chair an educational session for the Chemistry in Cancer Research Working Group (CICR) at the American Association for Cancer Research (AACR) annual meeting on Saturday, April 12 at the San Diego Convention Center.
Dr. Munk's session will highlight the unique developmental challenges of safely manufacturing highly potent active pharmaceutical ingredients (APIs) used in cancer drugs. Speakers from Genzyme Corporation, SRI International, Infinity Pharmaceuticals, and Abbott Laboratories will participate in the session, titled "From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 4: Chemical Development: Translating a Potent Agent into a Registered Product."
About Ash Stevens, Inc.
Headquartered in Detroit, Ash Stevens, Inc. (ASI) was founded in 1962 to service the chemical research needs of the Federal Government. ASI has extensive experience in the development and scale-up of commercial cancer APIs and shares a longstanding and successful relationship with the National Cancer Institute. ASI has a total of 11 FDA approved drug substances in its portfolio. The company has more than 50 employees and holds patents in both medicinal and process chemistry. For more information, visit www. ashstevens. com.
# # #
